Detail
Článek
Web zdroj
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Monitoring EBV infection, MSI, PDL-1 expression, Her-2/neu amplification as a biomarker for PD-1 inhibition in gastric cancer

L. Stanek, R. Gurlich, Z. Musil, L. Havluj, A. Whitley

. 2022 ; 123 (2) : 83-86.

Jazyk angličtina Země Slovensko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22026097

BACKGROUND: The anti-PD-1 monoclonal antibody pembrolizumab has been shown to be associated with a good response in patients with metastatic gastric cancer. Excellent therapeutic results of pembrolizumab have been shown in patients with tumours showing a high microsatellite instability (MSI) and Epstein–Barr virus (EBV) positivity. GOAL: This is a retrospective study of 40 bioptic specimens from the patients, who underwent gastrectomy for gastric carcinoma. The goal of the study was to identify biomarkers (EBV, MLH-1, PDL-1 expression) that are potentially relevant for selecting the patients, who may benefit from PD-1 inhibition therapy. METHODS: Immunohistochemical (IHC) expression of PDL-1 and MSI, cytogenetic FISH amplification of the HER-2/neu gene and polymerase chain reaction of EBV RNA, including charge quantification, were performed in selected patients with metastatic or advanced gastric cancer. RESULTS: EBV-encoded RNA was detected in nine patients. None of them exhibited Her-2 overexpression or CMV infection. PD-L1 was detected in twelve patients. Ten patients were MLH1 positive. All nine cases of EBV infection showed a high expression of PD-L1 and MLH-1 (Tab. 1, Ref. 14).

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22026097
003      
CZ-PrNML
005      
20230110134042.0
007      
ta
008      
221102s2022 xo fs 000 0|eng||
009      
AR
024    0_
$a 10.4149/BLL_2022_013 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xo
100    1_
$a Staněk, Libor $7 _AN091685 $u Third Faculty of Medicine, Charles University in Prague, Department of Surgery, Prague, Czech Republic
245    10
$a Monitoring EBV infection, MSI, PDL-1 expression, Her-2/neu amplification as a biomarker for PD-1 inhibition in gastric cancer / $c L. Stanek, R. Gurlich, Z. Musil, L. Havluj, A. Whitley
504    __
$a Literatura
520    9_
$a BACKGROUND: The anti-PD-1 monoclonal antibody pembrolizumab has been shown to be associated with a good response in patients with metastatic gastric cancer. Excellent therapeutic results of pembrolizumab have been shown in patients with tumours showing a high microsatellite instability (MSI) and Epstein–Barr virus (EBV) positivity. GOAL: This is a retrospective study of 40 bioptic specimens from the patients, who underwent gastrectomy for gastric carcinoma. The goal of the study was to identify biomarkers (EBV, MLH-1, PDL-1 expression) that are potentially relevant for selecting the patients, who may benefit from PD-1 inhibition therapy. METHODS: Immunohistochemical (IHC) expression of PDL-1 and MSI, cytogenetic FISH amplification of the HER-2/neu gene and polymerase chain reaction of EBV RNA, including charge quantification, were performed in selected patients with metastatic or advanced gastric cancer. RESULTS: EBV-encoded RNA was detected in nine patients. None of them exhibited Her-2 overexpression or CMV infection. PD-L1 was detected in twelve patients. Ten patients were MLH1 positive. All nine cases of EBV infection showed a high expression of PD-L1 and MLH-1 (Tab. 1, Ref. 14).
650    _7
$a senioři $7 D000368 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
650    _7
$a lidé středního věku $7 D008875 $2 czmesh
650    _7
$a infekce virem Epsteina-Barrové $x diagnóza $x imunologie $7 D020031 $2 czmesh
650    _7
$a mikrosatelitní nestabilita $7 D053842 $2 czmesh
650    _7
$a antigeny CD274 $x analýza $x imunologie $7 D060890 $2 czmesh
650    _7
$a receptor erbB-2 $x analýza $x imunologie $7 D018719 $2 czmesh
650    _7
$a MutL homolog 1 $x analýza $x imunologie $7 D000070957 $2 czmesh
650    17
$a biologické markery $x analýza $7 D015415 $2 czmesh
650    17
$a nádory žaludku $x imunologie $x patofyziologie $7 D013274 $2 czmesh
650    _7
$a odběr biologického vzorku $7 D013048 $2 czmesh
650    _7
$a výběr pacientů $7 D018579 $2 czmesh
650    _7
$a exprese genu $7 D015870 $2 czmesh
650    _7
$a klinické laboratorní techniky $x metody $7 D019411 $2 czmesh
650    _7
$a retrospektivní studie $7 D012189 $2 czmesh
655    _7
$a práce podpořená grantem $7 D013485 $2 czmesh
700    1_
$a Gürlich, Robert, $d 1964- $7 xx0000272 $u Third Faculty of Medicine, Charles University in Prague, Department of Surgery, Prague, Czech Republic
700    1_
$a Musil, Zdeněk $7 xx0107856 $u First Faculty of Medicine, Charles University in Prague, Institute of Biology and Clinical Genetic, Prague, Czech Republic
700    1_
$a Havlůj, Lukáš $7 xx0210907 $u Third Faculty of Medicine, Charles University in Prague, Department of Surgery, Prague, Czech Republic
700    1_
$a Whitley, A $7 _AN117976 $u Third Faculty of Medicine, Charles University in Prague, Department of Surgery, Prague, Czech Republic
773    0_
$t Bratislavské lekárske listy $x 0006-9248 $g Roč. 123, č. 2 (2022), s. 83-86 $w MED00000845
856    41
$u http://www.elis.sk/download_file.php?product_id=7528&session_id=5hob67buame1h4jbqk1qin6737 $y plný text volně přístupný
910    __
$a ABA008 $b online $c 1067 $y p $z 0
990    __
$a 20221101161338 $b ABA008
991    __
$a 20230110134038 $b ABA008
999    __
$a ok $b bmc $g 1855741 $s 1177401
BAS    __
$a 3
BMC    __
$a 2022 $b 123 $c 2 $d 83-86 $i 0006-9248 $m Bratislavské lekárske listy $x MED00000845
LZP    __
$c NLK189 $d 20221217 $a NLK 2022-22/kv

Najít záznam

Citační ukazatele

Možnosti archivace